Galen Biopharma India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -505.21%
- Ebitda -505.21%
- Net Worth -146.50%
- Total Assets %
About Galen Biopharma India
Galen Biopharma India Private Limited (GBIPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 July 2020 (Four years and six months 25 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Madhavi Madaan and Babita Khanduri serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U73100MH2020PTC342833
- Company No.
342833
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jul 2020
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Galen Biopharma India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhavi Madaan  | Director | 22-Aug-2022 | Current |
| Babita Khanduri | Director | 22-Aug-2022 | Current |
Financial Performance of Galen Biopharma India.
Galen Biopharma India Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 505.21% decrease in profit. The company's net worth observed a substantial decline by a decrease of 146.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Galen Biopharma India?
In 2022, Galen Biopharma India had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Xpo Solutions Worldwide Private LimitedMadhavi Madaan is a mutual person
Xpoodle Tech Private LimitedMadhavi Madaan is a mutual person
Xs Productions India Private LimitedMadhavi Madaan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Galen Biopharma India?
Galen Biopharma India has a workforce of 0 employees as of Mar 24, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Galen Biopharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Galen Biopharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
